Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/27/22 | $175,000,000 | Series B |
Deep Track Capital Eventide Asset Management Farallon Capital Management Frazier Healthcare Partners Humboldt Fund Marshall Wace Millennium Management PFM Health Sciences  Pura Vida Investments RA Capital Management Surveyor Capital | undisclosed |
